07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

8041<br />

surface (CS) antibodies are produced by patients with pemphigus. The titer of anti-CS antibodies<br />

generally correlates with disease activity of pemphigus. See Method Description for special information<br />

pertaining to Herpes gestationis (pemphigoid) and paraneoplastic pemphigus.<br />

Useful For: Confirming a diagnosis of pemphigoid, pemphigus, epidermolysis bullosa acquisita, or<br />

bullous lupus erythematosus Monitoring therapeutic response in patients with pemphigus<br />

Interpretation: Indirect immunofluorescence (IF) testing may be diagnostic when histologic or direct<br />

IF studies are only suggestive, nonspecific, or negative. Anti-cell surface (CS) antibodies correlate with a<br />

diagnosis of pemphigus. Anti-basement zone (BMZ) antibodies correlate with a diagnosis of bullous<br />

pemphigoid, cicatricial pemphigoid, epidermolysis bullosa acquisita (EBA), or bullous eruption of lupus<br />

erythematosus (LE). If serum contains anti-BMZ antibodies, the pattern of fluorescence on sodium<br />

chloride(NaCl)-split skin substrate helps distinguish pemphigoid from EBA and bullous LE. Staining of<br />

the roof (epidermal side) or both epidermal and dermal sides of NaCl-split skin correlates with the<br />

diagnosis of pemphigoid, while fluorescence localized only to the dermal side of the split-skin substrate<br />

correlates with either EBA or bullous LE.<br />

Reference Values:<br />

Report includes presence and titer of circulating antibodies. If serum contains BMZ antibodies on<br />

split-skin substrate, patterns will be reported as: 1) epidermal pattern, consistent with pemphigoid or 2)<br />

dermal pattern, consistent with epidermolysis bullosa acquisita.<br />

Negative in normal individuals. See Results of IF <strong>Test</strong>ing* in Cutaneous Immunofluorescence <strong>Test</strong>ing<br />

in Special Instructions.<br />

Clinical References: 1. Immunopathology of the Skin. Edited by EH Beutner, TP Chorzelski, V<br />

Kumar. 3rd edition. New York, Wiley <strong>Medical</strong> Publication, 1987 2. Gammon WR, Briggaman RA, Inman<br />

AO 3rd, et al: Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by<br />

indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol<br />

1984;82:139-144<br />

Cutaneous Immunofluorescence, Biopsy<br />

Clinical Information: Skin or mucosal tissue from patients with autoimmune bullous diseases,<br />

connective tissue disease, vasculitis, lichen planus, and other inflammatory conditions often contains<br />

bound immunoglobulin, complement, and/or fibrinogen. Biopsy specimens are examined for the presence<br />

of bound IgG, IgM, IgA, third component of complement (C3), and fibrinogen. For your convenience, we<br />

recommend utilizing cascade testing for celiac disease. Cascade testing ensures that testing proceeds in an<br />

algorithmic fashion. The following cascades are available; select the appropriate 1 for your specific<br />

patient situation. Algorithms for the cascade tests are available in Special Instructions. -CDCOM/89201<br />

Celiac Disease Comprehensive Cascade: complete testing including HLA DQ -CDSP/89199 Celiac<br />

Disease Serology Cascade: complete testing excluding HLA DQ -CDGF/89200 Celiac Disease<br />

Comprehensive Cascade for Patients on a Gluten-Free Diet: for patients already adhering to a gluten-free<br />

diet To order individual tests, see Celiac Disease Diagnostic <strong>Test</strong>ing Algorithm in Special Instructions.<br />

Useful For: Confirming a diagnosis of bullous pemphigoid, cicatricial pemphigoid, variants of<br />

pemphigoid, all types of pemphigus, dermatitis herpetiformis, linear IgA bullous dermatosis, chronic<br />

bullous disease of childhood, epidermolysis bullosa acquisita, porphyria cutanea tarda, bullous eruption of<br />

lupus erythematosus, herpes gestationis, and atypical or mixed forms of bullous disease, systemic lupus<br />

erythematosus, discoid lupus erythematosus, or other variants, vasculitis, lichen planus, and other<br />

inflammatory diseases.<br />

Interpretation: In pemphigus, direct immunofluorescence (IF) testing will show deposition of IgG, or<br />

rarely IgA, and often complement C3 (C3) at the cell surface (intercelluar substances). In bullous<br />

pemphigoid and cicatricial pemphigoid, direct IF study demonstrates deposition of IgG and C3 at the<br />

basement membrane zone (BMZ) in a linear pattern. In cicatricial pemphigoid, a disease uncommonly<br />

associated with circulating anti-BMZ antibodies, direct IF testing is particularly useful. Biopsy from<br />

patients with dermatitis herpetiformis will show IgA concentrated in dermal papillae and/or in a granular<br />

Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong><strong>Laboratories</strong>.com Page 563

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!